Altered factor VII activating protease expression in murine hepatic fibrosis and its influence on hepatic stellate cells

Liver International

Volumn 29, Issue 5, 2009, Pages 686-691

  Roderfeld, Martin ^a   Weiskirchen, Ralf ^b   Atanasova, Srebrena ^a   Gressner, Axel M ^b   Preissner, Klaus T ^a   Roeb, Elke ^a   Kanse, Sandip M ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Fibrosis; FSAP; HSC; Liver; PDGF

Indexed keywords

FACTOR VII ACTIVATING PROTEASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR BB; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER FIBROSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; STELLATE CELL;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; ENZYME ACTIVATION; HEPATIC STELLATE CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, SPRAGUE-DAWLEY; SERINE ENDOPEPTIDASES; STATISTICS, NONPARAMETRIC;

EID: 64749111974     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01897.x     Document Type: Article

References (39)

1. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38: 38-53.
2. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007; 46: 955-75.
3. Roderfeld M, Hemmann S, Roeb E. Mechanisms of fibrinolysis in chronic liver injury (with special emphasis on MMPs and TIMPs). Z Gastroenterol 2007; 45: 25-33.
4. Iredale JP. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117: 539-48.
5. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001; 21: 311-35.
6. Eng FJ, Friedman SL. Fibrogenesis I. New insights into hepatic stellate cell activation: The simple becomes complex. Am J Physiol Gastrointest Liver Physiol 2000; 279: 7-11.
7. Roderfeld M, Weiskirchen R, Wagner S, et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J 2006; 20: 444-54.
8. Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front Biosci 2002; 7: 1720-6.
9. Conway AM, Rakhit S, Pyne S, Pyne NJ. Platelet-derived-growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: Role of pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase. Biochem J 1999; 337: 171-7.
10. Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 2007; 46: 1064-74.
11. Czochra P, Klopcic B, Meyer E, et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 2006; 45: 419-28.
12. Gonzalo T, Beljaars L, van de BM, et al. Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. J Pharmacol Exp Ther 2007; 321: 856-65.
13. Yoshiji H, Noguchi R, Kuriyama S, et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288: 907-13.
14. Borkham-Kamphorst E, Stoll D, Gressner AM, Weiskirchen R. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem Biophys Res Commun 2004; 321: 413-23.
15. Choi-Miura NH, Yoda M, Saito K, Takahashi K, Tomita M. Identification of the substrates for plasma hyaluronan binding protein. Biol Pharm Bull 2001; 24: 140-3.
16. Kanse SM, Parahuleva M, Muhl L, Kemkes-Matthes B, Sedding D, Preissner KT. Factor VII-activating protease (FSAP): Vascular functions and role in atherosclerosis. Thromb Haemost 2008; 99: 286-9.
17. Altincicek B, Shibamiya A, Trusheim H, et al. A positively charged cluster in the epidermal growth factor-like domain of Factor VII-activating protease (FSAP) is essential for polyanion binding. Biochem J 2006; 394: 687-92.
18. Choi-Miura NH, Tobe T, Sumiya J, et al. Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: It has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator. J Biochem 1996; 119: 1157-65.
19. Kannemeier C, Feussner A, Stohr HA, Weisse J, Preissner KT, Romisch J. Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme. Eur J Biochem 2001; 268: 3789-96.
20. Nakazawa F, Kannemeier C, Shibamiya A, et al. Extracellular RNA is a natural cofactor for the (auto-)activation of factor VII-activating protease (FSAP). Biochem J 2005; 385: 831-8.
21. Kannemeier C, Al-Fakhri N, Preissner KT, Kanse SM. Factor VII-activating protease (FSAP) inhibits growth factor-mediated cell proliferation and migration of vascular smooth muscle cells. FASEB J 2004; 18: 728-30.
22. Sedding D, Daniel JM, Muhl L, et al. The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation. J Exp Med 2006; 203: 2801-7.
23. Shibamiya A, Muhl L, Tannert-Otto S, Preissner KT, Kanse SM. Nucleic acids potentiate factor VII activating protease (FSAP)-mediated cleavage of platelet derived growth factor-BB and inhibition of vascular smooth muscle cell proliferation. Biochem J 2007; 404: 45-50.
24. Etscheid M, Beer N, Kress JA, Seitz R, Dodt J. Inhibition of bFGF/ EGF-dependent endothelial cell proliferation by the hyaluronan-binding protease from human plasma. Eur J Cell Biol 2004; 82: 597-604.
25. Etscheid M, Beer N, Dodt J. The hyaluronan-binding protease upregulates ERK1/2 and PI3K/Akt signalling pathways in fibroblasts and stimulates cell proliferation and migration. Cell Signal 2005; 17: 1486-94.
26. Kress JA, Seitz R, Dodt J, Etscheid M. Induction of intracellular signalling in human endothelial cells by the hyaluronan-binding protease involves two distinct pathways. Biol Chem 2006; 387: 1275-83.
27. Willeit J, Kiechl S, Weimer T, et al. Marburg I polymorphism of factor VII-activating protease: A prominent risk predictor of carotid stenosis. Circulation 2003; 107: 667-70.
28. Choi-Miura NH, Otsuyama K, Sano Y, Saito K, Takahashi K, Tomita M. Hepatic injury-specific conversion of mouse plasma hyaluronan binding protein to the active hetero-dimer form. Biol Pharm Bull 2001; 24: 892-6.
29. Henkel C, Roderfeld M, Weiskirchen R, et al. Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. Proteomics 2006; 6: 6538-48.
30. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-17.
31. Schafer S, Zerbe O, Gressner AM. The synthesis of proteoglycans in fat-storing cells of rat liver. Hepatology 1987; 7: 680-7.
32. Abriss B, Hollweg G, Gressner AM, Weiskirchen R. Adenoviral-mediated transfer of p53 or retinoblastoma protein blocks cell proliferation and induces apoptosis in culture-activated hepatic stellate cells. J Hepatol 2003; 38: 169-78.
33. Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R. Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 2004; 84: 766-77.
34. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: E45.
35. Rosner B, Grove D. Use of the Mann-Whitney U-test for clustered data. Stat Med 1999; 18: 1387-400.
36. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast. One function, multiple origins. Am J Pathol 2007; 170: 1807-16.
37. Gonzalez-Cuevas J, Bueno-Topete M, Armendariz-Borunda J. Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue. J Gastroenterol Hepatol 2006; 21: 1544-54.
38. Salgado S, Garcia J, Vera J, et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000; 2: 545-51.
39. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22: 83-96.